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Abstract. New treatments for malaria are urgently needed in areas such as Thailand
where highly drug-resistant strains of Plasmodium falciparum are prevalent. Mefloquine
is rapidly losing efficacy and conventional doses of halofantrine are ineffective. We there
fore used pharmacokinetic simulation to design an extended-dose halofantrine regimen and
tested it in 26 soldiers stationed along the Thai-Cambodian border. Halofantrine was given
after meals as three doses of 500 mg each at 4-hr intervals on the first day, followed by
500 mg a day for six days (total dose 4.5 g). Twenty-six soldiers treated with quinine
tetracycline for seven days (Q7T7) served as controls. There were no significant differences
in efficacy between halofantrine and Q7T7 (P> 0.1) as assessed by cure rate (92% versus
85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time
(93 hr versus 99 hr). Halofantrine was better tolerated than Q7T7. The side effects score
was lower (2 versus 11; P < 0.00 1), there were less days on which side effects occurred
(2.0 days versus 5.5 days; P < 0.001), and fewer patients had adverse effects on every
treatment day (4% versus 42%; P < 0.01). High-dose halofantrine is as effective and better
tolerated than quinine-tetracycline for multidrug-resistant falciparum malaria.
New treatments are urgently needed for drug
resistant falciparum malaria. Mefloquine is but
the latest in a series of antimalarials that have
rapidly lost efficacy after being introduced for
the treatment of malaria in the border regions of
Thailand,' where drug-resistant Plasmodium fal
ciparum parasites are particularly prevalent.2
Halofantrine is a promising new antimalarial,
butcross-resistancewithmefloquineisa poten
tial problem3 and the drug is absorbed erratical
ly.4 In this study, we attempted to overcome
poor absorption by using a repetitive dosage reg
imen and administering halofantrine with meals,
which has been shown to increase its bioavail
ability.5
Even when given with meals, however, the
manufacturer's (SmithKline Beecham, Welwyn,
Garden City, UK) recommended dose of halo
fantrine (500 mg taken three times at 6-hr inter
vals) cured only 50% of P. falciparum infections
acquired along the Thai-Cambodian border.6
Drug levels one week after treatment were high
er in the patients who were cured, suggesting
that a regimen capable of producing sustained,
high, blood levels might be successful. We used
pharmacokimetic simulation to devise such a reg
imen and them tested it in soldiers stationed
along the Thai-Cambodian border. The efficacy
and side effects of halofantrine were compared
with those of quinine-tetracycline given for sev
en days (Q7T7), the standard in-hospital treat
ment for uncomplicated falciparum malaria in
this region.7
Patients
PATIENTS AND METHODS
Study subjects were recruited from male Thai
volunteer soldiers 18 years of age or older who
were occupationally exposed to malaria along
the Thai-Cambodian border. Patients with cere
bral malaria, renal failure, hepatic impairment,
shock, hemoglobinuria, or with mixed infections
(e.g., P. falciparum and P. vivax) were excluded.
Study volunteers were hospitalized in a non
malariousareafor21 days and then examined
one week after discharge. The reappearance of
parasites in the peripheral blood within a month
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of treatmentwas thereforedue tolatetreatment
failureratherthanreinfection.
Volunteers were randomized by a computer
generated random numbers list to receive seven
days of quinine (650 mg orally every 8 hr) with
tetracycline (250 mg orally every 6 hi) or oral
halofantrine. Each halofantrine dose of 500 mg
was given 30 mm after a meal containing soy
milk, rice, and meat. Halofantrine was given
three times at 4-hr intervals on the first day, and
500 mg was then given every morning for six
days (total dose 4.5 g). Pharmacokinetic simu
lation of this regimen was performed using phar
macokinetic software (PCNONLIN; Statistical
Consultants, Inc., Lexington, KY) and relied on
previously derived pharmacokinetic parameters
(Shmuklarsky Mi and others, unpublished data).
Laboratory investigations
Routine hematologic and biochemical tests
were performed on admission and after one
week in all cases, more often if they were ab
normal. Standard thick and thin blood films were
examined for P. falciparum parasites twice a day
until two successive smears were negative (no
asexual parasites in 200 microscopic fields),
them every other day until discharge and at fol
low-up. Parasitemia was determined by the
number of asexual parasites per 200 white blood
cells corrected for the patient's actual leukocyte
count.
Invitrodrug-sensitivitytestingwas performed
using the radioisotopemethod describedby
Webster and others,2 except that drug dilutions
were performed manually ratherthan by ma
chine. The 50% inhibitory concentration (IC@)
was the concentration of antimalarial drug re
quired to inhibit parasite uptake of 3H-hypoxan
thine by 50%.
Adverse drug effects
Side effects elicited by checklist were record
ed for each treatment day on a standardized code
sheet. Symptoms were assessed as mild or se
vere using predetermined criteria agreed on by
the three physicians responsible for gathering
side effects data. These criteria were numerical
whenever possible. For example, one or two
loose stools was considered mild diarrhea, three
or more was severe; one or two episodes of
vomiting was considered mild, three or more
was severe.Attemptswere made tobe asobjec
tive as possible when numerical measures were
not applicable. For example, a headache noted
by the patient that did not interfere with sleep
was considered mild, and a headache requiring
repeated symptomatic treatment and prohibiting
sleep was severe. Adverse effects code sheets
were filled out at approximately the same time
every morning and the patient was carefully in
structed to report any symptom noted during the
previous24-hr period.Frequent checks were
made during the study to ensure that the criteria
were reproduciblewhen sideeffectsdatawere
gatheredby differentphysicians.
A sideeffectsscorewas tabulatedforeach
patientwithoutknowledge ofthetreatmentdrug.
A scoreof one was givenforeverymild symp
tom and a scoreof threeforeveryseveresymp
tom. Patients were assigned a score every day
derived by adding the number of mild (one point
per symptom) and severe (threepoints per
symptom) effectsreportedfortheprevious24-
hr period.Ifno sideeffectswere reported,the
score for that day would be zero. The total side
effects score was the sum of the seven daily
scores, one score for each day of treatment.
Symptoms reported by the patient during the day
prior to treatment were not included in the tab
ulationsincethey could not be attributedwith
certaintytotheeffectsof medication.
Data analysis
The parasite clearance time (PCT) was the
number of hours between the first dose of med
ication and the first of two successive negative
blood films; the fever clearance time (FCT) was
the interval between the first dose and the time
at which the patient became and remained afe
brile (< 37.2Â°C).The study groups were com
pared using the Student's r-test for normally dis
tributed values and the Mann-Whitney U test for
those not normally distributed. Two-tailed tests
of significance were calculated in all cases.
Efficacy
RESULTS
There were no significant differences on ad
mission between the 26 patients randomized to
receive Q7T7 and the 26 who received halofan
trine (Table 1). Both regimens were effective
CharacteristicTreatmentHalofantrineQuinine-tetracyclineParasitemia/p.lt24,095
(1,341â€”97,295)16,834 (1,012â€”91,212)IC50
of halofantrine (ng/ml)t1.6 (0.1â€”18.8)0.8(0.1â€”5.6)ICyj
of quinine (ng/ml)t159(56â€”574)130(42â€”641)Age
(years)@25.0 (5.0)24.2(4.8)Weight
(kg)@57.9 (5.2)61.1(7.0)Leukocytes/p.l16,913
(2,171)6,528 (2,206)
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TABLE 1
Comparability of study groups on admission
* There were no significant differences (P > 0.1) between groups for any admission characteristic.
t Values are the median (range).
@ values are the mean (SD).
(Figure 1), but neither was significantly better.
Parasites were cleared initially in all 52 patients;
the PCT was 82 hr (95% confidenceinterval
[CI]71â€”93hi)forhalofantrineand 81 hr (95%
CI 72â€”90hi) for quinine(P > 0.1).Asexual
parasitesreappearedin two halofantrine-treated
patients(ondays 21 and 28)and infourpatients
who had received quinine (on days 17, 19, 24,
and 28). Although halofantrine gave a slighter
higher cure rate than quinine (92% versus 85%)
and a shorter FCT (93 hr versus 99 hi), these
differences were not significant (P> 0.1).
Halofantrineplasma concentrationswere de
termined at periodic intervals during treatment
of 10 cured malaria patients (detailed methods
and results to be given in a separate report). The
mean Â± SD halofantrinemaximum concentra
tion(Cmax) was 1,924Â±927 mg/mlon day one
and 2,582 Â± 852 ng/ml on day six.The mean
Â± SD halofantrine concentrations on day eight
were 511 Â± 404 ng/ml. A limited number of
plasma drug concentrations were determined in
the two halofantrine treatment failures.
Plasmodium falciparum isolates from 47 pa
tients were tested for in vitro sensitivity to hal
ofantrine.The median IC50was 0.9ng/ml (range
0.1â€”18.8 ng/ml); (95% CI 0.6â€”2.0 ng/ml). Iso
lates from the two halofantrine treatment failures
were resistant to halofantrine in vitro; one isolate
had the highest IC@ found (18.8 ng/ml) while
the IC@ of the other (3.2 ng/ml) was above the
upper 95% CI.
Adverse effects
Halofantrine was better tolerated than qui
nine-tetracycline(Figure2).The median sideef
fectsscoreinthehalofantrine-treatedgroup was
2 (range0â€”12)compared with 11 (range0â€”38)
in the quinine-treated group P < 0.001). The
median number of days on which side effects
were reported during therapy was 2 (range 0â€”7)
for halofantrmne and 5.5 (range 0â€”7)for quinine
(P < 0.001). Only one (4%) halofantrine-treated
patient complained of side effects every treat
ment day compared with 11 patients (42%) re
ceiving quinine-tetracycline (P < 0.01, by
chi-square test with Yates' correction). Self-lim
ited diarrhea on the first or second treatment day
occurred in 16 patients (62%) and was the most
common side effect of halofantrine (Table 2).
Other common adverse effects were dizziness
(19%) and vomiting (19%). In no case were side
effects severe enough to require a change in
medication.
FIGURE 1. Treatment efficacy (mean with upper
95% confidence interval). There were no significant
differencesincurerate,parasiteclearancetime(PCT),
orfeverclearancetime(FCT)bctweeapatientsreated
withhalofantrineorquinine-tetracycline(P> 0.1).h
= hours.
â€¢QUININE@ HALOFANTRINE
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CURE RATE (%) PCT (h) FCT(Vi)
TreatmentQuinine
SymptomHalofantrinetetracyclineDiarrhea16(62)9(35)Hearing
difficulty2 (8)14(54)Tinnit s1
(4)13(50)Vomiting5(19)8(31)Nauseat4
(15)7(27)Dizziness5(19)2(8)Abdominal
pain1 (4)5(19)Headache2
(8)1(4)Blurred
vision1 (4)2(8)Restlessness1
(4)0 (0)
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D HALOFANTRINEâ€¢QUININE TABLE 2
Number (%) of patients with side effects*
14
12
10
* Includes any treatment emergent symptom reported during the first
seven days that was not present in the 24 hr prior to admission.
t All patients with vomiting also had nausea, but nausea was present
prior to admission in several cases and was therefore not tabulated as a
treatment emergent symptom.
SIDE EFFECTS SCORE DAYS OF SIDE EFFECTS
FIGURE 2. Adverse effects (median with upper
95% confidence interval). Treatment with quinine-tet
racyclineforsevendaysgavea highersideeffects
scoreandsideeffectsoccurredon moredaysthanwith
halofantrine (P < 0.001).
Neither regimen was associated with serious
hematologic or biochemical toxicity. Four qui
nine- and two halofantrine-treated patients (P>
0.1) had normal serum transaminase levels on
admission and minor, transient elevations of se
rum alanime aminotransferase (ALT) one week
later. The ALT levels subsequently returned to
normal ineverycase.
DISCUSSION
This study demonstrates that halofantrime can
be used successfullytotreatmultidrug-resistant
falciparum malaria when given as a loading dose
(1,500 mg given over an 8-hr period), followed
by a maintenance dose of 500 mg per day for
six days. This regimen was designed to rapidly
achieve effective plasma drug concentrations
and to maintain effective levels throughout the
treatment period. Computer simulation based on
the known pharmacokimetics of the drug was
used to optimize the dosage schedule. This hal
ofantrine regimen was as effective as quinine
tetracycline and better tolerated (Figures 1 and
2).Compared withtheusualregimenof500 mg
given at 6-hr intervalswithoutregardto food
intake, the halofantrine plasma concentrations
are substantially higher using the extended reg
imen with food. For example, comparing our
data with a study of Thai patients with acute
uncomplicated falciparum malaria reveals that
the mean halofantrine concentrations on day one
and day six were approximately two-fold and
12-fold higher, respectively.8
We attempted to understand why halofantrine
treatmentwas unsuccessfulintwo of the26 pa
tientS.Previous investigatorshave attributed
therapeuticfailureto poor drug absorption,4'6'9
but thiswas not the major factorin our two
cases of laterecrudescence.One failurewas
clearlytheresultof infectionwith a highlyre
sistant parasite. The IC@ for halofantrine in this
case was 18.8 ng/ml, the highest value among
the 47 isolates tested. Parasites whose IC@ ex
ceeds 2.0 mg/ml are considered halofantrine-re
sistant.'Â° There was no evidence of poor drug
absorption; this patient's peak halofantrine level
on day one (2,495 ng/ml) surpassed the study
mean (1,924 ng/ml). The second patient was
also clearly infected with a resistant parasite; the
halofantrine IC@ (3.2 ng/ml) exceeded the upper
95% CI. The small number of plasma halofan
trine concentrations available in this case sug
gest that suboptimal drug levels could have
combined with parasite drug-resistance to pro
duce a poor therapeutic outcome. The halofan
trime concentration op day eight (406 ng/ml) was
slightly lower than the mean Â±SD value of 511
Â±404 ng/ml. Treatment failure could theoreti
cally result from a population of highly resistant
parasites being selected by drug pressure. This
is an unlikely explanation for our two treatment
failures. The halofantrine IC@ of recrudescent
isolates was lower than for pretreatment isolates
in both cases; 16.5 ng/ml compared with 18.8
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